MELK and adrenal cortex carcinoma: Analysis of the TCGA and E-TABM-311 databases showed that the estimated overall survival (OS) of patients with ACC that overexpressed MELK was shorter than patients with low MELK mRNA expression (TCGA: 4.3 years vs. 10.8 years, p < 0.001; E-TABM-311: 3.1 years vs. 7.7 years, p = 0.004) (Fig. 2D, E).